Immunocore to present at upcoming investor conferences

Rhea-AI Summary

Immunocore Holdings plc (IMCR) announced its participation in upcoming investor conferences to discuss its transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases. The presentations will be webcast live and accessible on the company's website.

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in April:

• Needham Virtual Healthcare Conference
  Fireside Chat: Wednesday, April 10, 2024, at 11:00 a.m. EDT
  

• Canaccord Horizons in Oncology
  Panel: T-Cell Engagers for Solid Tumors: Monday, April 15, 2024, at 4:00 p.m. EDT
  

• Kempen Life Sciences Conference
  1x1 and small group meetings: Tuesday, April 16, 2024
  
  

Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time. 

About Immunocore 
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK (tebentafusp) has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom. 

CONTACT:  
Immunocore  
Sébastien Desprez, Head of Communications 
T: +44 (0) 7458030732 
E: mailto:sebastien.desprez@immunocore.com         
Follow on Twitter: @Immunocore  

Investor Relations   
Clayton Robertson, Head of Investor Relations 
T: +1 215-384-4781 
E: ir@immunocore.com 

When will Immunocore participate in the Needham Virtual Healthcare Conference?

Immunocore will participate in the Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:00 a.m. EDT.

What will be discussed in the Canaccord Horizons in Oncology Panel?

The Canaccord Horizons in Oncology Panel will focus on T-Cell Engagers for Solid Tumors on Monday, April 15, 2024, at 4:00 p.m. EDT.

Where can the presentations be accessed?

The presentations can be accessed by visiting 'Events' under 'News & Events' via the 'Investors' section of Immunocore's website at www.immunocore.com.

Will there be a replay of the presentations available?

Yes, a replay of the presentations will be made available for a time after the events.